BioHarvest Sciences Inc. (NASDAQ:BHST – Get Free Report)’s stock price dropped 5.5% on Thursday . The stock traded as low as $2.75 and last traded at $2.75. 36,352 shares were traded during trading, an increase of 61% from the average session volume of 22,582 shares. The stock had previously closed at $2.91.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.00.
Get Our Latest Stock Analysis on BioHarvest Sciences
BioHarvest Sciences Stock Up 2.0%
BioHarvest Sciences (NASDAQ:BHST – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $8.50 million. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%. Equities research analysts predict that BioHarvest Sciences Inc. will post -0.45 EPS for the current fiscal year.
Institutional Trading of BioHarvest Sciences
Several institutional investors and hedge funds have recently bought and sold shares of BHST. Alyeska Investment Group L.P. acquired a new position in BioHarvest Sciences in the fourth quarter valued at $3,929,000. Thompson Siegel & Walmsley LLC acquired a new stake in shares of BioHarvest Sciences during the fourth quarter worth about $1,945,000. Evercore Wealth Management LLC acquired a new stake in shares of BioHarvest Sciences during the fourth quarter worth about $724,000. True North Advisors LLC grew its holdings in shares of BioHarvest Sciences by 381.0% during the first quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock worth $729,000 after buying an additional 133,085 shares during the last quarter. Finally, King Luther Capital Management Corp purchased a new position in shares of BioHarvest Sciences during the fourth quarter worth about $208,000.
About BioHarvest Sciences
BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.
The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.
Featured Stories
- Five stocks we like better than BioHarvest Sciences
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
